Bioage Labs, Inc. declined 2.62% in intraday trading. RTW Biotech, an investment fund specializing in life sciences, reported underperforming its benchmarks in 2024, despite a 52% increase in total net asset value due to the acquisition of Arix Bioscience. The net asset value per ordinary share fell 4.7%, which may have contributed to the negative sentiment surrounding Bioage Labs, Inc.
Comments
No comments yet